FDA Panel Disapproves Of HIFU For Prostate Cancer
HIFU, which has been used in other countries for about 15 years, is marketed in Europe by EDAP TMS, a French company operating in the US as EDAP Technology. This robotic technology would be the first device of its kind to get approved in the USA.
HIFU consists of a treatment module designed to connect a control console to an endorectal probe device. After the patient has been anaesthetised, a urologist robotically controls the probe for insertion into the rectum, enabling the device to deliver ultrasonic energy to a focused portion of the prostate. In the process, high-intensity waves from an ultrasound imaging transducer in the probe generate intensive heat (85-95C). This causes ablation of cancerous tissue while preserving the apex, sphincter, and rectum, according to EDAP.
However, the Gastroenterology and Urology Panel of the FDA's Medical Devices Advisory Committee expressed concerns about the paucity of data available from HIFU sponsor's research findings that were presented as part of its US premarket approval application.
A majority of panel members voted 'No' to the question regarding a reasonable assurance that the therapy is safe. In addition, panel members voted unanimously against reasonable assurance that the treatment is effective.
During the hearing, EDAP presenters emphasised the "body of evidence" strongly supports the approval of HIFU in the US. The benefits of a noninvasive and localised therapy with exact energy delivery, they said, outweigh the risks for urinary obstructive morbidity. The side effects from HIFU are "not dissimilar" to those caused by other prostate cancer treatments, including radiation therapy, EDAP pointed out.
FDA presenters, however, reviewed EDAP's submission documents carefully, citing these deficiencies: lack of data and safety concerns (ie, a 28% cumulative positive biopsy rate two years after HIFU treatment among participants in a nonrandomised trial).
Inderbir Gill, MD, chair of the University of Southern California, Los Angeles, Institute of Urology, is among those who support the HIFU treatment. HIFU may not be perfect but all ablation technologies have similar biopsy rates, Dr. Gill told panel members. "It's about patient choice."
HIFU has been used in 40,000 patients during a 15-year period, said Dr. Gill, adding that the device has never been suspended or withdrawn from the market.
Image credit: Harvard Medical School
Published on : Tue, 5 Aug 2014
The best patient care is your ultimate goal. To achieve this requires confident diagnosis even with daily increases in patient throughput. Built on the foundation of Mindray’s continuous customer insights into clinical needs and the inheritance from...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
Open high-field efficiency with patient-centric architecture OASIS™ is a new generation of MR systems, providing a high degree of diagnostic confidence and extraordinary patient comfort. With this unique scanner, Hitachi combines best high-field performance...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
Shown to improve comfort in 93% of patients who reported moderate to severe discomfort with standard compression technology2 Curved, unique design mirrors the shape of a woman’s breast to reduce pinching and apply uniform compression over the entire...